Drugs / IO103
Trials 9 · a red edge is where a trial was stopped
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 9 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IO103 | “Stimulation with a PD-L1 peptide (IO103), activates these cells to exhibit inflammatory and anti-regulatory functions that include cytotoxicity against PD-L1-expressing target cells.” PMID 33240282 ↗ Nov 20205“IO103 is a anti-cancer therapy consisting of a synthetic PD-L1-derived peptide.” NCT03714529 ↗ |
| Known as | PD-L1 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03939234 ↗ |
| Known as | PD-L1 peptide | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03850522 ↗ |
| Action | Activate | “Activation of IDO or PD-L1 specific T-cells through vaccination with the IDO and PD-L1 peptides (IO102-IO103) will boost natural killing of cancer cells and counteract immune...” NCT05077709 ↗ |
| Modality | Vaccine | “present first-in-human study of vaccination with IO103” PMID 33240282 ↗ Nov 2020 |
| Route | Subcutaneous | “Subcutaneous vaccinations with IO103 with the adjuvant Montanide ISA 51 was given up to fifteen times during 1 year.” PMID 33240282 ↗ Nov 2020 |